Buch will lead the company’s research and development, manufacturing and operations, quality and regulatory, business development, and innovation functions. The company said he will provide strategic and execution-focused guidance to help the company achieve major milestones for its Allurion Gastric Balloon.
“We are thrilled to welcome Ojas to Allurion as our chief operating officer,” Founder and CEO Shantanu Gaur said in a news release. “His extensive industry experience and proven leadership skills will be instrumental as we continue to innovate and scale our business globally, while ensuring we uphold the highest quality standards as a publicly traded company.”
Buch has more than 25 years of healthcare industry experience. He has held roles of varying responsibility at GE HealthCare, St. Jude Medical (Abbott), CareFusion (Vyaire) and Philips. Most recently, he was president of Pentax Medical Americas.
“I am proud to serve Allurion at this exciting stage of its lifecycle and look forward to working with our team to advance Allurion’s vision to transform the lives of individuals through cutting-edge weight loss solutions,” Buch said.
Allurion develops a gastric balloon for weight loss. The swallowable balloon requires no surgery, endoscopy or anesthesia. Once swallowed, the balloon fills and remains in the stomach for approximately four months before self-emptying and passing out naturally.
The balloon pairs with the company’s Virtual Care Suite remote patient monitoring platform. Allurion partnered with Medtronic on the AI-powered platform midway through last year.
